Conestoga Capital Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q3
Sell
-3,096
Closed -$228K 115
2016
Q2
$228K Buy
+3,096
New +$219K 0.02% 105
2016
Q1
Sell
-3,096
Closed -$213K 114
2015
Q4
$213K Buy
+3,096
New +$205K 0.02% 111
2015
Q3
Sell
-3,096
Closed -$206K 110
2015
Q2
$206K Buy
+3,096
New +$204K 0.01% 112

Other funds holding BMY

Conestoga Capital Advisors's BMY Position: Q3 2016 in Review

Conestoga Capital Advisors sold out of Bristol-Myers Squibb (BMY) in Q3 2016, closing a stake of 3,096 shares — an estimated $228K sold.

Conestoga Capital Advisors first reported a position in BMY in Q2 2015 and held it in 3 quarters. The position peaked at $228K in Q2 2016. 1,522 funds tracked by Wall St. Rank hold BMY as of Q3 2016.

  • Conestoga Capital Advisors reported no remaining Bristol-Myers Squibb position as of Q3 2016 after selling out during the quarter.
  • Conestoga Capital Advisors sold 3,096 Bristol-Myers Squibb shares in Q3 2016, an estimated $228K.
  • Conestoga Capital Advisors first reported a position in Bristol-Myers Squibb in Q2 2015 and held it in 3 quarters.
  • Conestoga Capital Advisors's Bristol-Myers Squibb position peaked at $228K in Q2 2016.
  • 1,522 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2016.

Based on Conestoga Capital Advisors's 13F filing for Q3 2016, filed 11 Oct 2016.